New Market - August 18, 2026
NextCell selected as the only Swedish company in the EU-Japan Biotech Business Mission 2026
In parallel, the company is strengthening its local presence in Hong Kong by establishing an office and becoming a member of the Hong Kong-Shenzhen Innovation and Technology Park (HSITP).
New Market - July 16, 2026
Novo Nordisk receives European Commission approval of Wegovy pill as first oral GLP-1 for weight management
The European Commission (EC) has granted marketing authorisation for Wegovy pill (once-daily oral semaglutide 25 mg) for the treatment of adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.
New Market - July 14, 2026
FDA approves Leqembi Iqlik subcutaneous injection as a starting dose for early Alzheimer’s disease
BioArctic’s partner Eisai has announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection (US brand name: Leqembi Iqlik) as a starting dose for the treatment of early Alzheimer’s disease.
New Market - July 13, 2026
Sunresin has opened its first European site in Uppsala
The new facility, located at Uppsala Business Park, will serve as a European centre for chromatography resin development, process development, technical support and customer collaboration.
Biotech Business - July 10, 2026
Biovica refocuses US strategy and terminates agreement with Tempus AI
Biovica has, by mutual agreement, ended the reference laboratory agreement with Tempus AI, announced in May 2025.
Biotech Business - June 23, 2026
CHOSA Oncology establishes US presence in Boston
CHOSA Oncology has established a business presence in Boston, Massachusetts, marking an important strategic step in the company's US commercialization for Platin-DRP.
